Sanofi shares are trading higher after Chamber of Commerce tribunal dismissed BI's indemnification claim against Sanofi and confirmed that Sanofi shall not be liable to indemnify BI for any potential losses for the ongoing Zantac litigation in the U.S.
Portfolio Pulse from Benzinga Newsdesk
Sanofi shares are trading higher after a Chamber of Commerce tribunal dismissed BI's indemnification claim against Sanofi, confirming that Sanofi is not liable to indemnify BI for potential losses in the ongoing Zantac litigation in the U.S.
June 20, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's stock price is trading higher after a tribunal dismissed BI's indemnification claim, confirming that Sanofi is not liable for potential losses in the ongoing Zantac litigation.
The dismissal of BI's indemnification claim against Sanofi by the Chamber of Commerce tribunal is a positive development for Sanofi. This decision removes a potential financial burden from the company, which could have resulted in significant losses. As a result, investors are likely to view this news positively, leading to an increase in Sanofi's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100